Endostatin potentiates the antimitotic effects of paclitaxel (taxol) on endothelial cells (ECs). P125A-endostatin and taxol-treated ECs showed multipolar spindles and nuclear lobulation, leading to mitotic catastrophe and cell death. Induction of nuclear abnormalities was found to be dependent on b-catenin levels as wnt-mediated overexpression of b-catenin reversed the changes in nuclear morphology. These results prompted us to investigate whether antiangiogenic gene therapy and paclitaxel chemotherapy can synergistically inhibit angiogenesis and tumor growth. We first determined the effect of combination treatment in a transgenic mouse model of breast cancer. Intramuscular injection of recombinant adeno-associated virus type-2 virus induced sustained expression of P125A-endostatin. In vivo studies showed that combination therapy inhibited mammary cancer growth, delayed the onset of multifocal mammary adenocarcinomas, decreased tumor angiogenesis and increased survival in treated mice. In a second model, female athymic mice were orthotopically transplanted with a metastatic human breast cancer cell line. Antiangiogenic gene therapy in combination with paclitaxel inhibited tumor angiogenesis and lung/lymph-node metastasis in this model. These studies demonstrate cooperation between endostatin gene therapy and chemotherapy to inhibit tumor initiation, growth and metastasis.
INTRODUCTION
Breast cancer is the second leading cause of cancer deaths in women today. It is the sixth most lethal disease of women in the United States. Angiogenesis has a key role in the growth, invasion and metastasis of breast cancer. 1, 2 Increased vascular endothelial growth factor (VEGF) levels are associated with higher grade ductal carcinoma in situ, and the degree of microvessel density or angiogenesis is correlated with recurrence of invasive breast cancer in ductal carcinoma in situ. 3, 4 High microvessel density in premalignant lesions is also associated with higher risk of future breast cancer, 5 and higher microvessel density in invasive disease correlates with a greater likelihood of metastatic disease, 6 as well as shorter relapse-free and overall survival in patients with node-negative breast cancer. 7 Several chemotherapeutic and hormonal agents are currently used in the treatment of advanced breast cancer. Significant clinical benefit in progression-free survival is observed when anti-VEGF monoclonal antibody, bevacizumab, treatment is combined with paclitaxel. 8 Similarly, in many model systems antiangiogenic therapy is more effective when combined with chemotherapy. [9] [10] [11] [12] However, the mechanism behind the improved efficacy is not completely understood. One possibility is that the two reagents independently target different populations of cells such as the vascular endothelium and tumor cells. Another potential reason for synergy is thought to be vessel normalization mediated by antiangiogenic treatment, which could facilitate increased delivery of chemotherapeutic agents. Alternatively, chemotherapy might augment the effect of angiogenesis inhibitors on endothelial cells (ECs). To investigate the latter hypothesis, we used a mutant endostatin, P125A-endostatin along with paclitaxel to understand the synergy between an angiogenesis inhibitor and chemotherapy. Our studies show that a combination of paclitaxel and P125A-endostatin induced cytological changes in ECs, leading to enhanced endoreduplication and multipolar spindle formation. ECs were found to be vulnerable to mitotic catastrophe by reduced levels of b-catenin. We then determined the effect of sustained delivery of mutant endostatin by adeno-associated virus (AAV)-mediated gene therapy and paclitaxel treatment on breast cancer growth, angiogenesis and metastasis in mouse models of mammary carcinoma. Combination treatment inhibited lymph node and lung metastases of breast cancer cells. These studies show antiangiogenic gene therapy potentiates the effect of paclitaxel by modulating b-catenin levels and thereby increasing nuclear abnormalities in ECs.
RESULTS
Paclitaxel (taxol) inhibits microtubule dynamics of cytoskeletal elements resulting in mitotic arrest. Paclitaxel-treated cells show endoreduplication, a condition in which chromosomal duplication is not followed by separation of daughter chromosomes and nuclear abnormalities such as lobulations. 13, 14 Taxol treatment also affects the function of centrioles, a key organizer of microtubular assembly necessary for equal separation of chromosomes. Recent studies have identified a critical role of b-catenin in centriole function. 15, 16 As endostatin inhibits b-catenin levels in ECs by interfering with wnt-signaling pathway, 16 we hypothesized that endostatin treatment will potentiate the cytological changes induced by paclitaxel. Therefore, we investigated the effect of paclitaxel and endostatin on endoreduplication in the ECs.
Nuclear abnormalities
ECs (human umbilical vein endothelial cell (HUVEC)) were stained with antibodies to a/b-tubulin to identify changes in microtubular assembly. The nuclei were stained with propidium iodide and visualized by confocal imaging (Figures 1a-f) . Although paclitaxel treatment led to cytological changes, including microtubules and nuclear abnormalities (Figure 1c ), P125A-endostatin treatment did not affect the microtubule organization ( Figure 1b) . However, endostatin-treated cells showed a twofold increase (2.6% total cells) in nuclear abnormalities (Figure 1g ). In contrast, the paclitaxel-treated groups, either alone (Figure 1c ) or in combination with P125A-endostatin (Figure 1d ), showed increased nuclear abnormalities. About 10.3% of paclitaxel-treated cells (300 cells were counted in each group) showed nuclear abnormalities (Figure 1g ). Interestingly, when ECs were treated with both paclitaxel and P125A-endostatin, multipolar spindles (microtubule organizing centers) and nuclear abnormalities (multilobular) were seen in 23.4% of the total cells (Po0.05). A higher magnification image of the multilobular nucleus is shown in Figure 1e . A representative image of nuclei stained with propidium iodide from the combination treatment group is shown in Figure 1f . The multilobular nuclei was, however, surrounded by an intact nuclear membrane as indicated by lamin-B staining (data not shown). Figure 1g shows a comparison of cells with nuclear abnormalities from each treatment group. As nuclear abnormalities lead to mitotic crisis, we investigated whether combination treatment could synergistically inhibit EC proliferation. Isobolographic analysis of 5-bromo-2¢deoxyuridine incorporation in the presence of . These experiments were performed in triplicates and a total of X300 nuclei per group were counted in each experiment. **Denotes statistical significance (Po0.02). Isobologram shows synergy between paclitaxel and P125A-endostatin in inhibiting EC proliferation (h). Dotted line indicates the theoretical prediction of additive effect between paclitaxel and P125A-endostatin. BrdU incorporation was used to calculate inhibition of EC proliferation. The experiments were performed in triplicates.
P125A-endostatin and paclitaxel showed synergistic inhibition of cell proliferation (Figure 1h ). Observed 50% inhibitory concentration values for the combination groups were lower than the expected additive values (dotted line). These results demonstrate that endostatin potentiate the effect of paclitaxel on ECs.
Wnt signaling abrogates nuclear abnormalities Previous experiments suggested that a causative link between reduced b-catenin levels potentiates the nuclear abnormalities induced by paclitaxel. To further confirm the role of b-catenin in this process, we exogenously expressed b-catenin using an adenovirus construct. Data in Figure 2a infected with Ad-LacZ. Endostatin treatment decreased the b-catenin levels by 20%. Paclitaxel treatment showed about 27% decrease and the combination treatment resulted in 33% decrease in b-catenin when compared with Ad-wnt control. Wnt expression significantly increased the levels of b-catenin even in the cultures treated with both paclitaxel and P125A-endostatin. In parallel, we investigated the cytological changes that accompanied with wnt overexpression and determined whether the increased nuclear abnormalities seen in P125A-endostatin and paclitaxel treatment could be reversed by increasing the levels of b-catenin. Representative confocal images are shown in Figure 2b . These studies again showed that cells transduced with Ad-wnt had higher levels of b-catenin (red) when compared with control (Ad-LacZ)-treated cells under similar conditions (multiplicity of infection). Exogenous expression of wnt and the consequent upregulation of b-catenin levels decreased the number of cells showing nuclear abnormalities both in the paclitaxel-treated cells and in the cells treated with a combination of paclitaxel and P125A-endostatin. In this series of experiments, paclitaxel treatment alone showed about 22% of cells with multilobular and abnormal nuclei in the control cells, which was reduced to 5% in Ad-wnt-transduced cells.
Paclitaxel and P125A-endostatin treatment showed about 33% cells with nuclear abnormalities in the control cells (Ad-LacZ), which was significantly higher than the paclitaxel-treated control cells (Pp0.05). Ad-wnt transduction reduced the nuclear abnormalities from 33 to 9.0 % ( Figure 2c ). These studies show that reduced b-catenin levels potentiate paclitaxel-induced nuclear abnormalities and that a wnt-signaling-mediated increase in b-catenin could reverse this effect. On the basis of these results, we investigated whether a combination treatment with P125A-endostatin and paclitaxel can elicit better antitumor activity in vivo. As the efficacy of antiangiogenic therapy depends on continuously maintaining sufficient quantities of angiogenesis inhibitors in circulation, we used an AAV construct to deliver P125A-endostatin. AAV-P125A-endostatin and paclitaxel further reduced tumor incidence (only 20% of the treated mice were positive for tumor lesions). C3(1)Tag mice develop multiple lesions. Therefore, we determined the mean number of tumor lesions in each mouse over a period of time. Data in Figure 3b show that AAV-P125A-endostatin treatment reduced the number of tumor nodules per mouse when compared with the control group treated with AAV-LacZ. The control group showed a mean of 4.33 tumor nodules per mouse, whereas AAV-P125A-endostatin-treated mice had a mean of 1.8 tumor nodules per mouse. Cumulative tumor burden was also significantly reduced in the AAV-P125A-endostatin-treated mice. At week 24, for example, AAV-P125A-endostatin-treated mice showed a cumulative tumor volume of 96.7 mm 3 ( Figure 3c inset), compared with a volume of 2733 mm 3 in mice injected with AAV-LacZ (Figure 3c ), a 28.2-fold reduction in tumor burden. These data demonstrate that P125A-endostatin delays tumor initiation, reduces the number of tumor nodules and significantly decrease tumor growth. Another set of mice were injected with either AAV-LacZ or AAV-P125A-endostatin and then treated with paclitaxel. Mice treated with a combination of P125A-endostatin gene therapy and paclitaxel showed delayed cancer development (tumors appeared at week 21) compared with the AAV-LacZ and paclitaxel-treated group (tumors appeared at week 18). Tumor incidence was 100% in the AAV-LacZ and paclitaxel-injected group, whereas the AAV-P125A-endostatin and paclitaxel-treated group had only a 20% tumor incidence (Figure 3a) . Similarly, the cumulative tumor burden per mouse in the AAV-LacZ and paclitaxel group on week 25 was 1485 mm 3 ( Figure 3c ), whereas in animals treated with AAV-P125A-endostatin in combination with paclitaxel, tumor volume was 17.46 mm 3 (Figure 3c inset). The number of tumor nodules per mouse was also greatly reduced in the combination treatment group. The average number of tumor nodules per mouse in the paclitaxel-treated group at week 25 was 3.5, whereas the group treated with AAV-P125A-endostatin and paclitaxel showed an average of one tumor nodule per mouse at the same time point (Figure 3b ). Thus, tumor growth was not only delayed, but was significantly inhibited, when the mice were treated with the combination of paclitaxel and P125A-endostatinmediated gene therapy (Pp0.05). Mean endostatin levels in the AAV-P125A-endostatin-injected mice were 28.5±5.8 ng ml -1 at week 25. Mice treated with a combination of AAV-P125A-endostatin and paclitaxel showed serum levels of 26 ± 6.4 ng ml -1 endostatin at week 25. The group treated with AAV-LacZ alone or with AAV-LacZ and paclitaxel did not have any detectable amounts of human endostatin in their sera.
Mouse VEGF levels in the serum An increase in tumor mass often reflects the accumulation of tumor cell-derived growth factors in the serum. VEGF is one of the most critical angiogenic growth factors secreted by tumor cells. Therefore, serum samples were collected on week 16 and again on week 25 to estimate human VEGF levels in the different mouse groups. As shown in Figure 3d , there was an increase in mean VEGF levels in the sera of the mice injected with AAV-LacZ and AAV-LacZ and paclitaxel from weeks 16 to 25. Paclitaxel seems to have some effect in the early phase of tumor growth (week 16) as the mean VEGF was less (25.1 ± 8.9 pg ml À1 ) as compared with (44.4 ± 9.4 pg ml À1 ) to AAV-LacZ injected mice. In comparison, VEGF levels in the group of mice injected with AAV-P125A-endostatin did not increase from weeks 16 to 25, and actually it decreased from 23.4±15.8 to 16.5 ± 9.5 pg ml À1 , respectively. Antiangiogenic gene therapy combined with paclitaxel showed a more pronounced decrease in VEGF levels (17.9 pg ml À1 ± 9.4 at week 16 and 7.5 ± 6.8 pg ml À1 at week 25). Reduction in VEGF levels correlates with reduced tumor burden in the mice treated with AAV-endostatin and paclitaxel.
Decrease in tumor vasculature
Frozen tumor tissues from control and residual tumors from treatment groups were stained for blood vessels using rat anti-mouse CD31-phycoerythrin conjugate. Effect of combination treatment on tumor metastasis in intervention model of breast cancer Our previous experiments showed that the combination of antiangiogenic gene therapy and chemotherapy was better in preventing mammary cancer development (tumor initiation) and growth than either treatment alone. In a second series of experiments, we sought to determine whether combination treatment would be equally effective in an intervention model. The human metastatic breast cancer cell line, MDA-MB-231-luc, was used to establish tumors in mammary fat pads (orthotopic model). This model enabled us to follow tumor metastasis using noninvasive imaging methods. Figure 5a shows the growth and metastasis of MDA-MB-231-luc cells in athymic mice. By day 7 all the orthotopically transplanted mice showed luciferasepositive tumors. At this time, groups of mice were injected with AAV-LacZ or AAV-P125A-endostatin either alone or in combination with four cycles of paclitaxel chemotherapy. We specifically focused on measuring metastasis of tumors to the lungs and lymph nodes. By day 42 all the control mice showed extensive luciferase-positive areas in the lungs and lymph nodes, whereas P125A-endostatin gene therapy resulted in a modest decrease in metastasis. Paclitaxel treatment was better than endostatin gene therapy in reducing the amount of metastatic growth. At the end of the experiment, lungs and lymph nodes were dissected out and imaged ex vivo. Representative images of the lungs and lymph nodes are shown in Figure 5a and in vivo imaging data are summarized in Figure 5b . Luciferase-positive metastatic areas were reduced by 20% under AAV-P125A-endostatin treatment, whereas paclitaxel-treated mice showed a 43.4% reduction in the metastatic area. Combination treatment, however, showed a 71% inhibition, suggesting that antiangiogenic gene therapy along with chemotherapy significantly inhibited breast cancer metastasis.
Effects of combination therapy on breast cancer IV Subramanian et al 
Histopathology of the tumor tissues
Histopathology studies confirmed the absence of metastasis of tumors cells to the lungs in the mice injected with the combination of P125A-endostatin with paclitaxel. In this tumor model, paclitaxel at the doses used had little effect on the primary tumors. However, paclitaxel treatment inhibited metastasis of breast cancer cells to lungs. Representative images are shown in Figure 5c . In summary, combination treatment delayed tumor growth and reduced the tumor burden in the prevention model and inhibited lung and lymph node metastasis in the intervention model.
DISCUSSION
Present studies show that the antiangiogenic and antitumor activity of P125A-endostatin can be improved by coadministering paclitaxel, a microtubule stabilizing agent. P125A substitution in endostatin has been previously shown to improve the antiangiogenic activity. 17 Changes in amino-acid residues at this site seem to be well tolerated among different species; P125A substitution naturally occurs at this site of collagen type XVIII gene in chicken and Xenopus, whereas puffer fish has a glycine in place of a proline and Caenorhabditis elegans has a substitution with an aspartic acid. Improving the biological activity of endostatin by structural modifications will have potential use in clinical application. Our earlier studies have shown that the biological activity of endostatin can be increased by genetically engineering an integrintargeting sequence, Arg-Gly-Asp, 18 and amino peptidase-targeting sequence, Asn-Gly-Arg. 19 Another strategy is to increase the biological half-life of endostatin by genetically fusing to the Fc-region of immunoglobulin 20 and thereby improving its bioavailability.
Endostatin binding to ECs affects the activity of several transcription factors, cell-cycle modulators, angiogenic molecules and integrinmediated signaling. It was earlier shown that endostatin treatment can affect eight groups of signaling pathways, namely, iduronate-2-sulfatase, hypoxia inducible factor-1a, ephrins tumor necrosis factor, nuclear factor-kB, activator protein 1, coagulation cascades, signal transducers and activators of transcription-1 and E-26 transforming specific (ETS) domain containing transcription factor-1. 21, 22 Endostatin is also known to reduce the intracellular levels of b-catenin by interfering with the wnt-signaling pathway. 16 b-catenin acts as an inducer of cell proliferation in different tumors. 23, 24 Therefore, modulation of b-catenin levels can affect a multitude of cellular functions. For example, constitutive wnt signaling in malignant gastric adenocarcinoma shows higher levels of b-catenin in the nucleus. In these cells paclitaxel treatment increased the formation of multinuclear giant cells, which coincided with a decrease in wnt signaling and nuclear accumulation of b-catenin. 24 In PTEN-mutated prostate cancer cells, inhibition of wnt signaling increased chemosensitivity to paclitaxel. In these studies the levels of the total (cytoskeleton-associated) b-catenin did not change with WIF-1 (an inhibitor of wnt) overexpression, but the cytoplasmic b-catenin decreased. 25 On the contrary, paclitaxel treatment was found to reduce the cytosolic levels of b-catenin in nasopharyngeal carcinoma (TW-039) through pathways not involving the phosphorylation of b-catenin, which indicates that there might be possible crosstalk between the microtubule-and actin-based cytoskeletons. 26 Present studies show that microtubule stabilization can reduce b-catenin levels in ECs. It is not known whether the reduction in b-catenin in paclitaxel-treated ECs is mediated by phosphorylationdependent proteasomal degradation. Paclitaxel is a widely used chemotherapeutic agent and has been recently adapted to low-dose metronomic therapy to inhibit tumor angiogenesis. 27, 28 Our confocal studies of ECs treated with P125A-endostatin and paclitaxel showed increased nuclear abnormalities (multilobulation and endoreduplication) and multipolar spindles when compared with cells exposed to paclitaxel alone. As a consequence of multipolar spindle formation, orderly chromosomal segregation can be hampered, leading to endoreduplication and the formation of multilobular nuclei. This was confirmed by immunostaining of the nuclear inner membrane with antibodies to lamin-B (data not shown), which demonstrated that the multilobular nuclei had intact nuclear membrane. Our studies suggest that decreasing the levels of b-catenin by endostatin treatment potentiate paclitaxel-mediated nuclear and cellular abnormalities in ECs. Furthermore, reducing the levels of b-catenin sensitized ECs to paclitaxel-mediated inhibition of cell proliferation. Additionally, our studies show that abnormalities in mitotic spindle assembly and nuclei are exacerbated in the combination treatment group, suggesting that reduced levels of cytoplasmic b-catenin may contribute to the instability. We believe that modulation of b-catenin levels can potentiate paclitaxel-mediated changes in centriole dynamics. Preliminary studies (data not included) suggest that centriole number per cell increases in the combination treatment group. Exogenous overexpression of wnt reversed the effects of endostatin and paclitaxel significantly. These results support the notion that b-catenin has an important role in the increased mitotic defects seen in ECs treated with paclitaxel. Endostatin, in addition to inhibiting ECs, can also bind tumor cells directly and induce apoptosis. Previous studies have shown that endostatin binding to primary tumor cells from familial adenomatous polyposis activated programmed cell death pathway independent of wnt signaling. 29 Another study described that endostatin can inhibit colon cancer cell lines selectively by direct binding. Proliferation of a breast cancer cell line and Lewis lung carcinoma cells were not affected by endostatin treatment under similar conditions. 30 Our previous studies have shown that endostatin binds to avb1 integrin-expressing ovarian cancer cells and prevented their peritoneal seeding. 31, 32 These results suggest that the in vivo efficacy of endostatin gene therapy can be attributed to its effect on both endothelial and tumor cells. Present studies used a transgenic mouse model of mammary carcinoma. To find out whether endostatin can directly affect tumor cells from the transgenic mice, we used a cell line, M6, established from mammary tumors arising from C3(1)Tag mice. M6 cells proliferation was not inhibited by endostatin treatment (data not shown), which supports the previous findings that colon cancer cell lines are differentially sensitive to the direct effect of endostatin.
Potentiation of in vitro activity against ECs was further evaluated in vivo in two different tumor model systems. Our studies show that AAV-mediated delivery of mutant endostatin treatment in combination with paclitaxel was effective in the spontaneous tumor development model in which the mice showed reduced tumor burden, number of lesions that coincided with decreased vessel density. Synergy between antiangiogenic therapy and chemotherapy has been reported by others. Szentirmai et al. 33 showed improved inhibition of intracranial growth of glioblastoma by adenovirus-mediated gene therapy with endostatin in combination with soluble VEGF receptor 1. Another study showed synergy between chemotherapy and intratumoral delivery of a nonviral construct of endostatin. 34 Intratumoral gene delivery, however, is not a practical approach for cancer treatment. Our studies clearly demonstrate that systemic delivery and AAV-mediated expression of P125A-endostatin was effective in inhibiting lung and lymph node metastasis of breast cancer.
AAV-mediated gene therapy resulted in sustained expression of P125A-endostatin. 35, 36 This approach overcomes one of the major limitations, short serum half-life, of protein-based therapy with endostatin. In conclusion, our studies reiterate that AAV-based gene therapy can be used to improve the bioavailability and efficacy of endostatin. P125A-endostatin and paclitaxel significantly reduced the intracellular levels of b-catenin, and thereby perturbed the dynamic instability of microtubules in ECs. Combination of antiangiogenic gene therapy and paclitaxel treatment effectively inhibited tumor initiation and metastasis of breast cancer.
MATERIALS AND METHODS

Cell culture
E1A/E1B-transformed adherent 293 human embryonic kidney cells (Ad HEK293 cells) (Stratagene, La Jolla, CA, USA) were grown in Dulbecco's modified Eagle's medium (DMEM) medium (Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin and 2 mM L-glutamine (Invitrogen). HUVEC were grown in endothelial growth medium-2. Metastatic human breast cancer cells genetically tagged with luciferase (MDA-MB-231-luc) were obtained from Caliper Biosciences (Hopkinton, MA, USA). These cells were grown in DMEM medium (Invitrogen), supplemented with 10% fetal bovive serum and 1% penicillinstreptomycin and 2 mM L-glutamine (Invitrogen).
Cytotoxicity assay
Effect of paclitaxel and P125A-endostatin either alone or in combination on endothelial (HUVEC) proliferation was determined by isobolographic analysis. 37 HUVEC (5Â10 3 ) were seeded into 96-well plates. Recombinant P125A-endostatin expressed in Ad HEK293 cells was purified from culture supernatants by heparin-Sepharose affinity chromatography. P125A-endostatin (0.1, 1.0 and 10.0 mg ml À1 ) and paclitaxel (0.01, 0.05, 0.1, 0.2, 0.5 and 1.0 mg ml À1 ) were added in an array to triplicate sets of cultures. Cultures were first treated with paclitaxel for 1 h, followed by P125A-endostatin. Cell proliferation was determined by 5-bromo-2¢deoxyuridine incorporation (Roche Diagnostics, Indianapolis, IN, USA). Isobolographic analysis was carried out as described previously. 37, 38 Confocal and immunofluorescence microscopy HUVECs were plated onto eight-well chamber slides and were grown in media with low serum (M199 media containing 2% fetal bovive serum) for 16 h. The low serum containing media was then replaced with M199 media containing 50 ng ml À1 of VEGF. These cells were treated with either endostatin (20 mg ml À1 ; that is, 1.17 mM) or paclitaxel (50 nM) alone or in combination for 24 h. Untreated cells were used as controls in these experiments. Cells were fixed in 4% paraformaldehyde and processed for confocal studies. Immunofluorescence staining was carried out using rabbit anti-a/b tubulin antibody (Cell Signaling, Danvers, MA, USA); mouse anti-b-catenin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-rabbit IgG-Alexafluor 488 and anti-mouse IgG-Alexafluor 647 (Invitrogen) were used as the secondary antibodies. Rat anti-CD-31-PE was used for staining blood vessels. Nuclei were stained with either propidium iodide or 4¢-6-diamidino-2-phenylindole. Fields were chosen randomly from various sections to ensure objectivity of sampling. Digital images at Â600 magnification were acquired using the OIB format for the Olympus FluoView 1000 Confocal microscope (Leeds Precision Instruments, Minneapolis, MN, USA). Images were converted to TIFF format using either Confocal Assistant software version 4.02 (Clear State Solutions, Victoria, Australia) or Olympus FluoView Ver 1.5 viewer.
Western blot analysis
HUVECs were transduced with adenovirus expressing either wnt or LacZ (control) at 50 multiplicities of infection. After transduction, cells were grown for 16 h under low-serum (M199 media containing 2% fetal bovive serum)-containing media 16 h after addition of the Ad-wnt. Low-serum media was then replaced with M199 media containing 50 ng ml À1 of VEGF. These cells were treated either with endostatin (20 mg ml À1 ; that is, 1.7 mM) or paclitaxel (50 nM) alone or together for 24 h. Whole-cell lysates were prepared using RIPA buffer (50 mM Tris-Cl (pH 7.4), 1% NP-40, 2 mM EDTA (pH 8.0), 100 mM NaCl, 10 mM Na-orthovanadate, 1 mM PMSF, 20 mg ml À1 leupeptin and 20 mg ml À1 aprotinin). About 30 mg from each sample was loaded into each well. Protein bands were detected using rabbit anti-b-catenin antibody (Santa Cruz Biotechnology) and mouse anti-b-actin (Chemicon, Billerica, MA, USA) was used as a control. The b-catenin protein bands were scanned and normalized to b-actin bands using BioRad (Hercules, CA, USA) Gel Doc system.
Preparation, purification and titration of AAV-2 virus
The AVV type-2 (AAV-2) encoding the transgenes LacZ or P125A-endostatin virus were prepared, purified and titrated as previously described. 35 The AAV-LacZ was used as a control virus in all animal experiments.
Animal studies
Spontaneous tumor development (prevention) model. Sixty PRP-3 transgenic C3 (1)/SV40T AG were received from NCI-Frederick Cancer Research and Development Center (Maryland). Phenotypes of female C3 (1)/T AG transgenic mice have been previously described. 39 All animal experiments were carried out in accordance with an approved protocol from the Institutional Animal Care and Use Committee of the University of Minnesota. Mice were divided into four groups with fifteen mice per group. On weeks 8 and 9 of age, groups 1 and 3 were injected with 1Â10 9 viral particles (v.p.) of AAV-LacZ, whereas groups 2 and 4 were injected with 1Â10 9 v.p. of AAV-P125A-endostatin. Virus was injected intramuscularly at contralateral sites with a volume of 50 ml. Groups 3 and 4 were treated with paclitaxel 10 mg kg À1 intraperitoneally starting at week 8 (age of mice) in a volume of 200 ml. Groups 1 and 2 received equal volume of vehicle. Paclitaxel was injected twice a week until termination of the experiment. At the end of the study, serum samples were collected from mice to determine endostatin and VEGF levels using the Accucyte enzyme-linked immunosorbent assay system (Cytimmune Sciences Inc, College Park, MD, USA).
Orthotopic tumor (intervention) model. In this model, MDA-MB-231-luc cells (2Â10 6 ) were injected into the mammary fat pads of 6-to 8-week-old, female, athymic mice in a volume of 50 ml. On day 7, luciferin was injected intraperitoneally and the mice were imaged under isoflourane-induced anesthesia using a Xenogen imaging system (Caliper Instruments, Hopkinton, MA, USA). All the injected mice showed luciferase-positive tumors on day 7. Mice were then randomized into four groups. The mice in group I and III were injected intramuscularly with 1Â10 9 v.p. of AAV-LacZ and mice in group II and IV were injected with 1Â10 9 v.p. of AAV-P125A-endostatin on day 7. Paclitaxel (10 mg kg À1 ) was injected intraperitoneally twice a week for 4 weeks starting from day 21 to the mice in groups III and IV. Whole mice imaging was performed weekly and mice were euthanized on day 52, when the lungs and brachial lymph nodes were surgically removed and imaged ex vivo.
Tumor growth measurements and counting the number of nodules in the spontaneous tumor model. Tumor growth was monitored by periodic caliper measurements and the number of tumor nodules was also recorded. Tumor volume was calculated by the following formula: tumor volume (mm 3 )¼(aÂb 2 )/2, where a and b are the length and width in millimeter. Statistical significance between control and treated groups was determined by Student's t-test.
Vessel staining. Vessel staining and morphometric analysis were carried out using previously published methods. 40 Statistical significance was calculated by the Student's t-test.
Histopathology. Tissue samples were fixed in 10% buffered formalin and stained with hematoxylin and eosin stain.
Determination of endostatin and VEGF in mouse serum. Serum was collected from the mice at weeks 8 and 16, and also at the time of euthanization. Serum levels of endostatin and VEGF were determined by enzyme-linked immunosorbent assay (Accucyte, Cytimmune Sciences Inc., College Park, MD, USA and R&D Systems, Minneapolis, MN, USA, respectively).
ABBREVIATIONS
AAV-2, recombinant adeno-associated virus type-2; VEGF, vascular endothelial growth factor; P125A-endostatin, human endostatin in which proline 125 was
